CellPress is showcasing a collection of CTD² Network’s articles which will help develop precision therapeutics in cancer. Register for the Cell-NCI Symposium: Beyond Cancer Genomics Toward Precision Oncology taking place from October 4-6, 2021.
Publications
599 Publications Available
April 14, 2020
Nat Commun.
April 14, 2020
Cell Reports
Integrated analyses of multi-omics data indicate molecular and cellular differences in the clinical subtypes of high-grade serous ovarian cancer.
April 01, 2020
JCO Clin Cancer Inform.
Protein dependency analytic module integrated in TCPA measures key cancer dependencies in a context dependent manner. This analysis suggests that protein expression data are a highly valuable information resource for understanding tumor vulnerabilities and identifying therapeutic opportunities.
April 01, 2020
Translational Oncology
In vitro and in vivo studies conducted by CTD2 scientists at Emory University demonstrate that combination of JNK inhibitor, AS602801 with androgen receptor inhibitor, enzalutamide synergistically inhibit proliferation, migration, invasion, and prevent tumor growth in prostate cancer.
March 24, 2020
Nature Communications
Chemical biology approach reveals metabolic heterogeneity in cellular subtypes. This study suggests targeting both glucose reporter 1 and pyruvate dehydrogenase, components of glycolysis and mitochondrial metabolism, inhibit cancer cell invasion.
March 24, 2020
Scientific Reports
DFCI scientists identified XL177A as potent irreversible inhibitor of USP7, a deubiquitinating enzyme. This study indicated that TP53 mutational status predicted inhibitory response across several cancer lineages; demonstrates TP53 mutational status as a biomarker for response to USP7.
March 16, 2020
Cancer Cell
Study showed that combinatorial therapy with MLN4924, a drug that clears misfolded proteins, and anti-PD1, an immune-checkpoint blockade, enhances clinical responses in cancer patients with microsatellite instability.
March 10, 2020
NPJ Genomic Medicine
Scientists at Stanford CTD2 Center showed that MethylMix, a tool to identify methylation driver genes in cancer, can predict DNA methylation profiles in whole slide cancer histopathology images. This analysis provides new insights into the link between histopathological and molecular data.
March 03, 2020
Cell Reports
Researchers emphasize the influence of inherited germline variants in immune infiltration patterns of the tumor microenvironment. This study may help in understanding the predictors of response to immunotherapy.
Pages
.